Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

计划入组 480 人 · 首次发布于 2025 年 6 月 4 日

Viaskin® Peanut (DBV712) Expanded Access Protocol

首次发布于 2020 年 5 月 1 日

Safety Study of Viaskin Peanut to Treat Peanut Allergy

计划入组 393 人 · 首次发布于 2016 年 9 月 27 日

Peanut(Palforzia 12 Mg (level 3), Palforzia 120 Mg (level 7), Palforzia 160 Mg (level 8), Palforzia 20 Mg (level 4), Palforzia 200 Mg (level 9), Palforzia 240 Mg (level 10), Palforzia 3 Mg (level 1), Palforzia 300 Mg (level 11), Palforzia 40 Mg (level 5), Palforzia 6 Mg (level 2), Palforzia 80 Mg (level 6), Palforzia Initial Dose Escalation)

Viaskin-OVA

Viaskin-rPT

DBV Technologies

France

Original Patch Company Inc.

United States

Orthocell Ltd

DBV Technologies Appoints Kevin Trapp as Chief Commercial Officer Ahead of Viaskin Peanut Patch BLA Submission

DBV Technologies Advances Viaskin Peanut Patch with FDA and EMA Support

DBV Technologies Concludes VITESSE Trial Screening for Viaskin Peanut Patch